TOT BIOPHARM International Company Limited (1875.HK)
HKD 1.89
(1.61%)
HKD 1.89
(1.61%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -5.94 Million CNY | 95.36% |
| 2022 | -128.24 Million CNY | -329.99% |
| 2021 | 55.76 Million CNY | 125.56% |
| 2020 | -218.12 Million CNY | 53.0% |
| 2019 | -464.1 Million CNY | -92.48% |
| 2018 | -241.12 Million CNY | -198.74% |
| 2017 | 244.2 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 34.65 Million CNY | 0.0% |
| 2023 Q2 | -110.77 Million CNY | 0.0% |
| 2023 Q4 | -5.94 Million CNY | 0.0% |
| 2023 FY | -5.94 Million CNY | 95.36% |
| 2022 FY | -128.24 Million CNY | -329.99% |
| 2022 Q2 | 92.26 Million CNY | 0.0% |
| 2022 Q4 | -147.34 Million CNY | 0.0% |
| 2021 Q4 | 55.76 Million CNY | 0.0% |
| 2021 FY | 55.76 Million CNY | 125.56% |
| 2021 Q2 | -81.99 Million CNY | 0.0% |
| 2020 FY | -218.12 Million CNY | 53.0% |
| 2020 Q4 | -218.12 Million CNY | 0.0% |
| 2020 Q2 | -105.66 Million CNY | 0.0% |
| 2019 Q4 | -464.1 Million CNY | 0.0% |
| 2019 FY | -464.1 Million CNY | -92.48% |
| 2018 FY | -241.12 Million CNY | -198.74% |
| 2017 FY | 244.2 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Uni-Bio Science Group Limited | -76.36 Million HKD | 92.21% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.26 Billion HKD | 100.113% |